Corvus Pharmaceuticals' Short Runway Overshadows Soquelitinib's Promising Trials

Corvus Pharmaceuticals (NASDAQ: CRVS ) is essentially a biopharmaceutical company that develops treatments for autoimmune conditions and cancer. Their leading candidate is Soquelitinib, an ITK inhibitor with anti-inflammatory and anti-tumor properties. Soquelitinib can be used forMy name is Myriam Hernandez Alvarez. I received the Electronics and Telecommunication Engineering degree from the Escuela Politecnica Nacional, Quito, Ecuador, the M.Sc. degree in computer science from Ohio University, Athens, OH, ...